All Updates

All Updates

icon
Filter
Partnerships
Recursion Pharmaceuticals partners with Helix to accelerate drug discovery through AI and genomic data
Precision Medicine
Jun 24, 2024
Last week:
Product updates
Eve Air Mobility unveils unmanned eVTOL prototype
Passenger eVTOL Aircraft
Yesterday
Product updates
Lilium advances POWER-ON, providing solutions with leading digital innovators
Passenger eVTOL Aircraft
Yesterday
Industry news
New South Korean space agency provides rundown of plans
Space Travel and Exploration Tech
Jul 20, 2024
Funding
GRO Biosciences raises USD 60.3 million in Series B funding to advance lead program into clinical trials and expand GRObio pipeline
Precision Medicine
Jul 19, 2024
Management news
Yooz announces new appointments in C-Suite
Business Expense Management
Jul 19, 2024
Regulation/policy
Airwallex secures license to expand retail investment offerings in Australia
FinTech Infrastructure
Jul 19, 2024
Partnerships
EHang collaborates with KC Smart Mobility to expand EH216-S sales and operations in China
Passenger eVTOL Aircraft
Jul 19, 2024
Industry news
China launches Gaofen-11 high-resolution intelligence satellite
Satellite Management
Jul 19, 2024
Industry news
France funds miniature satellite capture and inspection mission
Satellite Management
Jul 19, 2024
Partnerships
Funding
MyFloraDNA launches crowdfunding campaign to address peanut allergies using CRISPR technology
Crop Biotech
Jul 19, 2024
Precision Medicine

Precision Medicine

Jun 24, 2024

Recursion Pharmaceuticals partners with Helix to accelerate drug discovery through AI and genomic data

Partnerships

  • Utah-based AI biotech company Recursion Pharmaceuticals has entered a multi-year agreement with precision medicine genomic solutions provider Helix, to accelerate drug discovery using population health data and AI.

  • According to the agreement, Recursion will gain the rights to use de-identified clinico-genomic data provided by Helix, collected from consenting research participants across the US. It plans to use the obtained data to train its AI models to create biomarkers and form strategies for patient stratification across multiple diseases

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.